Movement Alert|10x Genomics, Inc. Intraday Rise 5.57% in Regular Trading, rebound follows digestion of ARK selling and earlier post-earnings pressure

Market Focus11-19 22:51

On November 19, 10x Genomics, Inc. rose 5.57% in Regular Trading, trading at $60.57 per share, with turnover of $10.957 million.

The move came as the market appeared to digest ARK Invest's disclosed sale of 107,658 shares on November 17, with buying interest returning after recent pressure tied to post-earnings target-price cuts and the CEO's previously disclosed share sale.

Earlier this month, the company reported third-quarter EPS of negative $0.15 on revenue of $150.667 million, both better than consensus, and raised full-year revenue guidance to $625 million-$635 million from $610 million-$630 million. Even so, sentiment had been weighed down by target-price reductions including UBS to $61 from $90, while CEO Serge Saxonov disclosed the sale of 31,000 shares at $62.90 for about $1.95 million. The latest session suggests some of that selling overhang is being absorbed.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment